iTeos Therapeutics, Inc.ITOS

Market cap

$358.57M

P/E ratio

	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022
Net income	-38	215	97
Depreciation and amortization	1	1	1
Stock-based compensation	4	14	22
Amortization/accretion of available-for-sale debt securities	-	-	-2
Change in operating lease right of use assets	-	0	0
Grants receivable	5	-4	3
Research and development tax credits receivable	0	1	-1
Refundable income taxes	-	-8	6
Prepaid expenses and other current assets	2	-12	-1
Accounts payable	2	2	3
Accrued expenses and other liabilities	3	10	3
Deferred income	2	3	0
Deferred revenue	-	281	-268
Unrecognized tax benefits	-	17	-22
Net cash (used in) provided by operating activities	-25	513	-111
Purchases of investments	-	-	445
Purchase of property and equipment	0	1	1
Purchase of other assets	0	0	0
Net cash used in investing activities	-0	-1	-446
Proceeds from Issuance of Common Stock	1	3	1
Proceeds from grants repayable	4	1	1
Net cash provided by financing activities	340	4	2
Effects of exchange rate changes on cash, cash equivalents and restricted cash	-	-	-9
Net (decrease) increase in cash, cash equivalents and restricted cash	316	512	-564
Conversion of Stock, Amount Converted	182	-	-
Capital expenditure included in accounts payable	-	0	0
Preferred Stock, Accretion of Redemption Discount	5	-	-
Settlement of preferred stock tranche right	4	-	-
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	-	6	0
Unrealized loss on available-for-sale securities	-	-	0
Cash paid for taxes	0	32	23